The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower

The recently published INSIGHT trial showed that starting HIV therapy earlier rather than later has benefit for patients 1. This should not come as a surprise considering the excellent suppressive power of current triple regimens.  The trial which enrolled 4685 Continue reading The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower

Does The Taxpayer Get Rewarded For Funding Such Studies?

Cabotegravir (S-1265744) is an integrase inhibitor similar to dolutegravir.  When formulated as a long-acting drug using crystalline nanoparticle technology it is called GSK’744 LAP.  When injected intramuscularly, ‘744 LAP it has a half-life of >1 month which makes it ideally Continue reading Does The Taxpayer Get Rewarded For Funding Such Studies?

Tenofovir, BMD and Monitoring of Renal Function

The approved tenofovir / Viread label lists not only standard nucleoside-class side effects but also – since an update in 2012 – makes mention of diminished bone mineral density (BMD) in the Warnings / Precautions section. Demonstrating that a particular drug affects Continue reading Tenofovir, BMD and Monitoring of Renal Function